Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Levi Strauss & Co. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.83 (market cap $4.49B), while Levi Strauss & Co. trades at $24.2 (market cap $9.48B). The key difference: Levi Strauss & Co. is far larger — about 2.1× ACADIA Pharmaceuticals Inc.'s market cap, and Levi Strauss & Co. pays a 2.27% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | LEVI | |
|---|---|---|
Market Cap | $4.49B | $9.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $24.83 |
52-Week Low | $20.06 | $17.92 |
Enterprise Value | $3.69B | $10.99B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Levi Strauss (LEVI) trades at $24.66, up 1.02% with bullish technical indicators and strong earnings momentum after three consecutive quarterly beats. The company demonstrates robust profitability with a 61.69% gross margin and 9.52% net margin, supported by a $29.00 analyst consensus price target representing 17.6% upside. Recent news highlights Q2 2026 earnings anticipation and strategic focus on women's apparel expansion.
Outlook remains positive with earnings growth and dividend stability, though risks include inflationary pressures and competitive retail dynamics. The stock's current valuation at 18.15x P/E appears reasonable given 29.19% ROE, but investors should monitor Q2 results on July 8 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
